<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35269901</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>08</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>08</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1422-0067</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>23</Volume>
            <Issue>5</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Mar</Month>
              <Day>02</Day>
            </PubDate>
          </JournalIssue>
          <Title>International journal of molecular sciences</Title>
          <ISOAbbreviation>Int J Mol Sci</ISOAbbreviation>
        </Journal>
        <ArticleTitle>The EPH/Ephrin System in Colorectal Cancer.</ArticleTitle>
        <ELocationID EIdType="pii" ValidYN="Y">2761</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.3390/ijms23052761</ELocationID>
        <Abstract>
          <AbstractText>The EPH/ephrin system constitutes a bidirectional signaling pathway comprised of a family of tyrosine kinase receptors in tandem with their plasma membrane-bound ligand (ephrins). Its significance in a wide variety of physiologic and pathologic processes has been recognized during the past decades. In carcinogenesis, EPH/ephrins coordinate a wide spectrum of pathologic processes, such as angiogenesis, vessel infiltration, and metastasis. Despite the recent advances in colorectal cancer (CRC) diagnosis and treatment, it remains a leading cause of death globally, accounting for 9.2% of all cancer deaths. A growing body of literature has been published lately revitalizing our scientific interest towards the role of EPH/ephrins in pathogenesis and the treatment of CRC. The aim of the present review is to present the recent CRC data which might lead to clinical practice changes in the future.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Papadakos</LastName>
            <ForeName>Stavros P</ForeName>
            <Initials>SP</Initials>
            <AffiliationInfo>
              <Affiliation>First Department of Pathology, Medical School, National and Kapodistrian University of Athens, 157 72 Athens, Greece.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Petrogiannopoulos</LastName>
            <ForeName>Leonidas</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>First Department of Pathology, Medical School, National and Kapodistrian University of Athens, 157 72 Athens, Greece.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pergaris</LastName>
            <ForeName>Alexandros</ForeName>
            <Initials>A</Initials>
            <Identifier Source="ORCID">0000-0002-4960-672X</Identifier>
            <AffiliationInfo>
              <Affiliation>First Department of Pathology, Medical School, National and Kapodistrian University of Athens, 157 72 Athens, Greece.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Theocharis</LastName>
            <ForeName>Stamatios</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>First Department of Pathology, Medical School, National and Kapodistrian University of Athens, 157 72 Athens, Greece.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>03</Month>
          <Day>02</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Int J Mol Sci</MedlineTA>
        <NlmUniqueID>101092791</NlmUniqueID>
        <ISSNLinking>1422-0067</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D036342">Ephrins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.10.1</RegistryNumber>
          <NameOfSubstance UI="D036081">Receptors, Eph Family</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D015179" MajorTopicYN="Y">Colorectal Neoplasms</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D036342" MajorTopicYN="Y">Ephrins</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009389" MajorTopicYN="N">Neovascularization, Pathologic</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D036081" MajorTopicYN="N">Receptors, Eph Family</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
          <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">EPHs</Keyword>
        <Keyword MajorTopicYN="N">biomarkers</Keyword>
        <Keyword MajorTopicYN="N">colon cancer</Keyword>
        <Keyword MajorTopicYN="N">diagnosis</Keyword>
        <Keyword MajorTopicYN="N">ephrins</Keyword>
        <Keyword MajorTopicYN="N">prognosis</Keyword>
        <Keyword MajorTopicYN="N">therapy</Keyword>
      </KeywordList>
      <CoiStatement>The authors declare no conflict of interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>31</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>26</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>27</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>10</Day>
          <Hour>15</Hour>
          <Minute>36</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>11</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>9</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35269901</ArticleId>
        <ArticleId IdType="pmc">PMC8910949</ArticleId>
        <ArticleId IdType="doi">10.3390/ijms23052761</ArticleId>
        <ArticleId IdType="pii">ijms23052761</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Pergaris A., Danas E., Goutas D., Sykaras A.G., Soranidis A., Theocharis S. Molecular Sciences The Clinical Impact of the EPH/Ephrin System in Cancer: Unwinding the Thread. Int. J. Mol. Sci. 2021;22:8412.  doi: 10.3390/ijms22168412.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/ijms22168412</ArticleId>
            <ArticleId IdType="pmc">PMC8395090</ArticleId>
            <ArticleId IdType="pubmed">34445116</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pasquale E.B. Eph receptor signalling casts a wide net on cell behaviour. Nat. Rev. Mol. Cell Biol. 2005;6:462–475. doi: 10.1038/nrm1662.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrm1662</ArticleId>
            <ArticleId IdType="pubmed">15928710</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pasquale E.B. EPH–ephrin Bidirectional Signaling in Physiology and Disease. Cell. 2008;133:38–52. doi: 10.1016/j.cell.2008.03.011.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2008.03.011</ArticleId>
            <ArticleId IdType="pubmed">18394988</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gaitanos T., Dudanova I., Sakkou M., Klein R., Paixão S.  Receptor Tyrosine Kinases: Family and Subfamilies. Springer; Cham, Switzerland: 2015. The Eph receptor family; pp. 165–264.</Citation>
        </Reference>
        <Reference>
          <Citation>Chatzizacharias N.A., Giaginis C.T., Agapitos E., Theocharis S.E. The role of ephrins’ receptors and ephrins’ ligands in normal placental development and disease. Expert Opin. Ther. Targets. 2014;18:269–275. doi: 10.1517/14728222.2014.864638.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1517/14728222.2014.864638</ArticleId>
            <ArticleId IdType="pubmed">24329716</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cejalvo T., Munoz J.J., Tobajas E., Alfaro D., García-Ceca J., Zapata A. Conditioned deletion of ephrinB1 and/or ephrinB2 in either thymocytes or thymic epithelial cells alters the organization of thymic medulla and favors the appearance of thymic epithelial cysts. Histochem. Cell Biol. 2015;143:517–529. doi: 10.1007/s00418-014-1296-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00418-014-1296-9</ArticleId>
            <ArticleId IdType="pubmed">25417117</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Darling T.K., Lamb T.J. Emerging roles for Eph receptors and ephrin ligands in immunity. Front. Immunol. 2019;10:1473. doi: 10.3389/fimmu.2019.01473.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fimmu.2019.01473</ArticleId>
            <ArticleId IdType="pmc">PMC6620610</ArticleId>
            <ArticleId IdType="pubmed">31333644</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim A., Seong K.M., Choi Y.Y., Shim S., Park S., Lee S.S. Inhibition of epha2 by dasatinib suppresses radiation-induced intestinal injury. Int. J. Mol. Sci. 2020;21:9096.  doi: 10.3390/ijms21239096.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/ijms21239096</ArticleId>
            <ArticleId IdType="pmc">PMC7730170</ArticleId>
            <ArticleId IdType="pubmed">33265912</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Grandi A., Zini I., Palese S., Giorgio C., Tognolini M., Marchesani F., Bruno S., Flammini L., Cantoni A.M., Castelli R., et al.  Targeting the Eph/ephrin system as anti-inflammatory strategy in IBD. Front. Pharmacol. 2019;10:691. doi: 10.3389/fphar.2019.00691.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fphar.2019.00691</ArticleId>
            <ArticleId IdType="pmc">PMC6606944</ArticleId>
            <ArticleId IdType="pubmed">31297055</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Suenobu S., Takakura N., Inada T., Yamada Y., Yuasa H., Zhang X.Q., Sakano S., Oike Y., Suda T. A role of EphB4 receptor and its ligand, ephrin-B2, in erythropoiesis. Biochem. Biophys. Res. Commun. 2002;293:1124–1131. doi: 10.1016/S0006-291X(02)00330-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0006-291X(02)00330-3</ArticleId>
            <ArticleId IdType="pubmed">12051776</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kwak H., Salvucci O., Weigert R., Martinez-Torrecuadrada J.L., Henkemeyer M., Poulos M.G., Butler J.M., Tosato G. Sinusoidal ephrin receptor EPHB4 controls hematopoietic progenitor cell mobilization from bone marrow. J. Clin. Investig. 2016;126:4554–4568. doi: 10.1172/JCI87848.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1172/JCI87848</ArticleId>
            <ArticleId IdType="pmc">PMC5127687</ArticleId>
            <ArticleId IdType="pubmed">27820703</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Janes P.W., Vail M.E., Ernst M., Scott A.M. Eph receptors in the immunosuppressive tumor microenvironment. Cancer Res. 2021;81:801–805. doi: 10.1158/0008-5472.CAN-20-3047.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-20-3047</ArticleId>
            <ArticleId IdType="pubmed">33177063</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Andretta E., Cartón-García F., Martínez-Barriocanal Á., De Marcondes P.G., Jimenez-Flores L.M., MacAya I., Bazzocco S., Bilic J., Rodrigues P., Nieto R., et al.  Investigation of the role of tyrosine kinase receptor EPHA3 in colorectal cancer. Sci. Rep. 2017;7:41576. doi: 10.1038/srep41576.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/srep41576</ArticleId>
            <ArticleId IdType="pmc">PMC5294649</ArticleId>
            <ArticleId IdType="pubmed">28169277</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mendoza R., Saha N., Momeni A., Gabutan E., Alawad M., Dehghani A., Diks J., Lin B., Wang D., Alshal M., et al.  Ephrin-A1 and the sheddase ADAM12 are upregulated in COVID-19. Heliyon. 2021;7:e07200. doi: 10.1016/j.heliyon.2021.e07200.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.heliyon.2021.e07200</ArticleId>
            <ArticleId IdType="pmc">PMC8165044</ArticleId>
            <ArticleId IdType="pubmed">34095559</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pasquale E.B. Eph receptors and ephrins in cancer: Bidirectional signalling and beyond. Nat. Rev. Cancer. 2010;10:165–180. doi: 10.1038/nrc2806.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrc2806</ArticleId>
            <ArticleId IdType="pmc">PMC2921274</ArticleId>
            <ArticleId IdType="pubmed">20179713</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zimmer M., Palmer A., Köhler J., Klein R. EphB-ephrinB bi-directional endocytosis terminates adhesion allowing contact mediated repulsion. Nat. Cell Biol. 2003;5:869–878. doi: 10.1038/ncb1045.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ncb1045</ArticleId>
            <ArticleId IdType="pubmed">12973358</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wilkinson D.G. Regulation of cell differentiation by Eph receptor and ephrin signaling. Cell Adh. Migr. 2014;8:339–348. doi: 10.4161/19336918.2014.970007.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4161/19336918.2014.970007</ArticleId>
            <ArticleId IdType="pmc">PMC4594526</ArticleId>
            <ArticleId IdType="pubmed">25482623</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee H.S., Nishanian T.G., Mood K., Bong Y.S., Daar I.O. EphrinB1 controls cell-cell junctions through the Par polarity complex. Nat. Cell Biol. 2008;10:979–986. doi: 10.1038/ncb1758.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ncb1758</ArticleId>
            <ArticleId IdType="pmc">PMC2614381</ArticleId>
            <ArticleId IdType="pubmed">18604196</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Miao H., Wang B. Eph/ephrin signaling in epithelial development and homeostasis. Int. J. Biochem. Cell Biol. 2009;41:762–770. doi: 10.1016/j.biocel.2008.07.019.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.biocel.2008.07.019</ArticleId>
            <ArticleId IdType="pmc">PMC3108796</ArticleId>
            <ArticleId IdType="pubmed">18761422</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>White B.E.P., Getsios S. Eph receptor and ephrin function in breast, gut, and skin epithelia. Cell Adhes. Migr. 2014;8:327–338. doi: 10.4161/19336918.2014.970012.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4161/19336918.2014.970012</ArticleId>
            <ArticleId IdType="pmc">PMC4594571</ArticleId>
            <ArticleId IdType="pubmed">25482622</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dopeso H., Mateo-Lozano S., Mazzolini R., Rodrigues P., Lagares-Tena L., Ceron J., Romero J., Esteves M., Landolfi S., Hernández-Losa J., et al.  The receptor tyrosine kinase EPHB4 has tumor suppressor activities in intestinal tumorigenesis. Cancer Res. 2009;69:7430–7438. doi: 10.1158/0008-5472.CAN-09-0706.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-09-0706</ArticleId>
            <ArticleId IdType="pubmed">19738063</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Leroy C., Fialin C., Sirvent A., Simon V., Urbaeh S., Poncet J., Robert B., Jouin P., Roche S. Quantitative phosphoproteomics reveals a cluster of tyrosine kinases that mediates src invasive activity in advanced colon carcinoma cells. Cancer Res. 2009;69:2279–2286. doi: 10.1158/0008-5472.CAN-08-2354.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-08-2354</ArticleId>
            <ArticleId IdType="pubmed">19276381</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Holmberg J., Genander M., Halford M.M., Annerén C., Sondell M., Chumley M.J., Silvany R.E., Henkemeyer M., Frisén J. EphB Receptors Coordinate Migration and Proliferation in the Intestinal Stem Cell Niche. Cell. 2006;125:1151–1163. doi: 10.1016/j.cell.2006.04.030.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2006.04.030</ArticleId>
            <ArticleId IdType="pubmed">16777604</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Klein R. Eph/ephrin signaling in morphogenesis, neural development and plasticity. Curr. Opin. Cell Biol. 2004;16:580–589. doi: 10.1016/j.ceb.2004.07.002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ceb.2004.07.002</ArticleId>
            <ArticleId IdType="pubmed">15363810</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Edwards C.M., Mundy G.R. Eph receptors and ephrin signaling pathways: A role in bone homeostasis. Int. J. Med. Sci. 2008;5:263–272. doi: 10.7150/ijms.5.263.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.7150/ijms.5.263</ArticleId>
            <ArticleId IdType="pmc">PMC2536716</ArticleId>
            <ArticleId IdType="pubmed">18797510</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wan Y., Yang J.S., Xu L.C., Huang X.J., Wang W., Xie M.J. Roles of Eph/ephrin bidirectional signaling during injury and recovery of the central nervous system. Neural Regen. Res. 2018;13:1313–1321. doi: 10.4103/1673-5374.235217.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4103/1673-5374.235217</ArticleId>
            <ArticleId IdType="pmc">PMC6108204</ArticleId>
            <ArticleId IdType="pubmed">30106032</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Singh A., Winterbottom E., Daar I.O. Eph/ephrin signaling in cell-cell and cell-substrate adhesion. Front. Biosci. 2012;17:473–497. doi: 10.2741/3939.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2741/3939</ArticleId>
            <ArticleId IdType="pmc">PMC6291014</ArticleId>
            <ArticleId IdType="pubmed">22201756</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sung H., Ferlay J., Siegel R.L., Laversanne M., Soerjomataram I., Jemal A., Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA. Cancer J. Clin. 2021;71:209–249. doi: 10.3322/caac.21660.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3322/caac.21660</ArticleId>
            <ArticleId IdType="pubmed">33538338</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kokko A., Laiho P., Lehtonen R., Korja S., Carvajal-Carmona L.G., Järvinen H., Mecklin J.P., Eng C., Schleutker J., Tomlinson I.P.M., et al.  EPHB2 germline variants in patients with colorectal cancer or hyperplastic polyposis. BMC Cancer. 2006;6:145.  doi: 10.1186/1471-2407-6-145.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1471-2407-6-145</ArticleId>
            <ArticleId IdType="pmc">PMC1513590</ArticleId>
            <ArticleId IdType="pubmed">16740153</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Scherer D., Deutelmoser H., Balavarca Y., Toth R., Habermann N., Buck K., Kap E.J., Botma A., Seibold P., Jansen L., et al.  Polymorphisms in the angiogenesis-related genes EFNB2, MMP2 and JAG1 are associated with survival of colorectal cancer patients. Int. J. Mol. Sci. 2020;21:5395.  doi: 10.3390/ijms21155395.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/ijms21155395</ArticleId>
            <ArticleId IdType="pmc">PMC7432124</ArticleId>
            <ArticleId IdType="pubmed">32751332</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mathot L., Kundu S., Ljungström V., Svedlund J., Moens L., Adlerteg T., Falk-Sörqvist E., Rendo V., Bellomo C., Mayrhofer M., et al.  Somatic ephrin receptor mutations are associated with metastasis in primary colorectal cancer. Cancer Res. 2017;77:1730–1740. doi: 10.1158/0008-5472.CAN-16-1921.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-16-1921</ArticleId>
            <ArticleId IdType="pubmed">28108514</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yekkala K., Baudino T.A., Martiny-Baron G., Korff T., Schaffner F., Esser N., Eggstein S., Marme D., Augustin H.G., Li S., et al.  Reduced expression of EphrinA1 (EFNA1) inhibits three-dimensional growth of HT29 colon carcinoma cells. Carcinogenesis. 2007;12:237–243.</Citation>
        </Reference>
        <Reference>
          <Citation>Eriksson O., Thulin Å., Asplund A., Hegde G., Navani S., Siegbahn A. Cross-talk between the Tissue Factor/coagulation factor VIIa complex and the tyrosine kinase receptor EphA2 in cancer. BMC Cancer. 2016;16:341.  doi: 10.1186/s12885-016-2375-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12885-016-2375-1</ArticleId>
            <ArticleId IdType="pmc">PMC4888641</ArticleId>
            <ArticleId IdType="pubmed">27246245</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li M., Yang C., Liu X., Yuan L., Zhang F., Wang M., Miao D., Gu X., Jiang S., Cui B., et al.  EphA3 promotes malignant transformation of colorectal epithelial cells by upregulating oncogenic pathways. Cancer Lett. 2016;383:195–203. doi: 10.1016/j.canlet.2016.10.004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.canlet.2016.10.004</ArticleId>
            <ArticleId IdType="pubmed">27721017</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu W., Ahmad S.A., Jung Y.D., Reinmuth N., Fan F., Bucana C.D., Ellis L.M. Coexpression of ephrin-Bs and their receptors in colon carcinoma. Cancer. 2002;94:934–939. doi: 10.1002/cncr.10122.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/cncr.10122</ArticleId>
            <ArticleId IdType="pubmed">11920461</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu Q., Lind G.E., Aasheim H.C., Micci F., Silins I., Tropé C.G., Nesland J.M., Lothe R.A., Suo Z. The EPH receptor Bs (EPHBs) promoters are unmethylated in colon and ovarian cancers. Epigenetics. 2007;2:237–243. doi: 10.4161/epi.2.4.5406.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4161/epi.2.4.5406</ArticleId>
            <ArticleId IdType="pubmed">18281782</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Larriba M.J., Valle N., Pálmer H.G., Ordóñez-Morán P., Álvarez-Díaz S., Becker K.F., Gamallo C., De Herreros A.G., González-Sancho J.M., Muñoz A. The inhibition of Wnt/β-catenin signalling by 1α,25-dihydroxyvitamin D3 is abrogated by Snail1 in human colon cancer cells. Endocr. Relat. Cancer. 2007;14:141–151. doi: 10.1677/ERC-06-0028.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1677/ERC-06-0028</ArticleId>
            <ArticleId IdType="pubmed">17395983</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chiu S.T., Chang K.J., Ting C.H., Shen H.C., Li H., Hsieh F.J. Over-expression of EphB3 enhances cell-cell contacts and suppresses tumor growth in HT-29 human colon cancer cells. Carcinogenesis. 2009;30:1475–1486. doi: 10.1093/carcin/bgp133.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/carcin/bgp133</ArticleId>
            <ArticleId IdType="pubmed">19483190</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Moser A.R., Luongo C., Gould K.A., McNeley M.K., Shoemaker A.R., Dove W.F. ApcMin: A mouse model for intestinal and mammary tumorigenesis. Eur. J. Cancer. 1995;31:1061–1064. doi: 10.1016/0959-8049(95)00181-H.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0959-8049(95)00181-H</ArticleId>
            <ArticleId IdType="pubmed">7576992</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Batlle E., Bacani J., Begthel H., Jonkeer S., Gregorieff A., Van De Born M., Malats N., Sancho E., Boon E., Pawson T., et al.  EphB receptor activity suppresses colorectal cancer progression. Nature. 2005;435:1126–1130. doi: 10.1038/nature03626.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature03626</ArticleId>
            <ArticleId IdType="pubmed">15973414</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lv J.H., Xia Q.Y., Wang J.J., Shen Q., Zhang J., Zhou X.J. EphB4 promotes the proliferation, invasion, and angiogenesis of human colorectal cancer. Exp. Mol. Pathol. 2016;100:402–408. doi: 10.1016/j.yexmp.2016.03.011.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.yexmp.2016.03.011</ArticleId>
            <ArticleId IdType="pubmed">27072105</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yekkala K., Baudino T.A. Inhibition of intestinal polyposis with reduced angiogenesis in Apc Min/+ mice due to decreases in c-Myc expression. Mol. Cancer Res. 2007;5:1296–1303. doi: 10.1158/1541-7786.MCR-07-0232.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1541-7786.MCR-07-0232</ArticleId>
            <ArticleId IdType="pubmed">18171987</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dominguez-Brauer C., Hao Z., Elia A.J., Fortin J.M., Nechanitzky R., Brauer P.M., Sheng Y., Mana M.D., Chio I.I.C., Haight J., et al.  Mule Regulates the Intestinal Stem Cell Niche via the Wnt Pathway and Targets EphB3 for Proteasomal and Lysosomal Degradation. Cell Stem Cell. 2016;19:205–216. doi: 10.1016/j.stem.2016.04.002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.stem.2016.04.002</ArticleId>
            <ArticleId IdType="pmc">PMC5193118</ArticleId>
            <ArticleId IdType="pubmed">27184401</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mathivanan S., Lim J.W.E., Tauro B.J., Ji H., Moritz R.L., Simpson R.J. Proteomics analysis of A33 immunoaffinity-purified exosomes released from the human colon tumor cell line LIM1215 reveals a tissue-specific protein signature. Mol. Cell. Proteom. 2010;9:197–208. doi: 10.1074/mcp.M900152-MCP200.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/mcp.M900152-MCP200</ArticleId>
            <ArticleId IdType="pmc">PMC2830834</ArticleId>
            <ArticleId IdType="pubmed">19837982</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ji H., Greening D.W., Barnes T.W., Lim J.W., Tauro B.J., Rai A., Xu R., Adda C., Mathivanan S., Zhao W., et al.  Proteome profiling of exosomes derived from human primary and metastatic colorectal cancer cells reveal differential expression of key metastatic factors and signal transduction components. Proteomics. 2013;13:1672–1686. doi: 10.1002/pmic.201200562.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/pmic.201200562</ArticleId>
            <ArticleId IdType="pubmed">23585443</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hryniuk A., Grainger S., Savory J.G.A., Lohnes D. Cdx1 and Cdx2 Function as tumor suppressors. J. Biol. Chem. 2014;289:33343–33354. doi: 10.1074/jbc.M114.583823.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.M114.583823</ArticleId>
            <ArticleId IdType="pmc">PMC4246091</ArticleId>
            <ArticleId IdType="pubmed">25320087</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhu Y., Hryniuk A., Foley T., Hess B., Lohnes D. Cdx2 Regulates Intestinal EphrinB1 through the Notch Pathway. Genes. 2021;12:188.  doi: 10.3390/genes12020188.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/genes12020188</ArticleId>
            <ArticleId IdType="pmc">PMC7911442</ArticleId>
            <ArticleId IdType="pubmed">33525395</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu W., Jung Y.D., Ahmad S.A., McCarty M.F., Stoeltzing O., Reinmuth N., Fan F., Ellis L.M. Effects of overexpression of ephrin-B2 on tumour growth in human colorectal cancer. Br. J. Cancer. 2004;90:1620–1626. doi: 10.1038/sj.bjc.6601723.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/sj.bjc.6601723</ArticleId>
            <ArticleId IdType="pmc">PMC2409715</ArticleId>
            <ArticleId IdType="pubmed">15083195</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alam S.K., Yadav V.K., Bajaj S., Datta A., Dutta S.K., Bhattacharyya M., Bhattacharya S., Debnath S., Roy S., Boardman L.A., et al.  DNA damage-induced ephrin-B2 reverse signaling promotes chemoresistance and drives EMT in colorectal carcinoma harboring mutant p53. Cell Death Differ. 2016;23:707–722. doi: 10.1038/cdd.2015.133.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/cdd.2015.133</ArticleId>
            <ArticleId IdType="pmc">PMC4986638</ArticleId>
            <ArticleId IdType="pubmed">26494468</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Potla L., Boghaert E.R., Armellino D., Frost P., Damle N.K. Reduced expression of EphrinA1 (EFNA1) inhibits three-dimensional growth of HT29 colon carcinoma cells. Cancer Lett. 2002;175:187–195. doi: 10.1016/S0304-3835(01)00613-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0304-3835(01)00613-9</ArticleId>
            <ArticleId IdType="pubmed">11741747</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ogawa K., Pasqualini R., Lindberg R.A., Kain R., Freeman A.L., Pasquale E.B. The ephrin-A1 ligand and its receptor, EphA2, are expressed during tumor neovascularization. Oncogene. 2000;19:6043–6052. doi: 10.1038/sj.onc.1204004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/sj.onc.1204004</ArticleId>
            <ArticleId IdType="pubmed">11146556</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hafner C., Schmitz G., Meyer S., Bataille F., Hau P., Langmann T., Dietmaier W., Landthaler M., Vogt T. Differential Gene Expression of Eph Receptors and Ephrins in Benign Human Tissues and Cancers. Clin. Chem. 2004;50:490–499. doi: 10.1373/clinchem.2003.026849.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1373/clinchem.2003.026849</ArticleId>
            <ArticleId IdType="pubmed">14726470</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guo D.L., Zhang J., Yuen S.T., Tsui W.Y., Chan A.S.Y., Ho C., Ji J., Leung S.Y., Chen X. Reduced expression of EphB2 that parallels invasion and metastasis in colorectal tumours. Carcinogenesis. 2006;27:454–464. doi: 10.1093/carcin/bgi259.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/carcin/bgi259</ArticleId>
            <ArticleId IdType="pubmed">16272170</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Herath N.I., Spanevello M.D., Doecke J.D., Smith F.M., Pouponnot C., Boyd A.W. Complex expression patterns of Eph receptor tyrosine kinases and their ephrin ligands in colorectal carcinogenesis. Eur. J. Cancer. 2012;48:753–762. doi: 10.1016/j.ejca.2011.07.003.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ejca.2011.07.003</ArticleId>
            <ArticleId IdType="pubmed">21852108</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Herath N.I., Doecke J., Leggett B.A., Boyd A.W. Epigenetic silencing of EphA1 expression in colorectal cancer is correlated with poor survival. Br. J. Cancer. 2009;100:1095–1102. doi: 10.1038/sj.bjc.6604970.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/sj.bjc.6604970</ArticleId>
            <ArticleId IdType="pmc">PMC2670002</ArticleId>
            <ArticleId IdType="pubmed">19277044</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Martini G., Cardone C., Vitiello P.P., Belli V., Napolitano S., Troiani T., Ciardiello D., Della Corte C.M., Morgillo F., Matrone N., et al.  EphA2 is a predictive biomarker of resistance and a potential therapeutic target for improving antiepidermal growth factor receptor therapy in colorectal cancer. Mol. Cancer Ther. 2019;18:845–855. doi: 10.1158/1535-7163.MCT-18-0539.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1535-7163.MCT-18-0539</ArticleId>
            <ArticleId IdType="pubmed">30824612</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Laiho P., Kokko A., Vanharanta S., Salovaara R., Sammalkorpi H., Järvinen H., Mecklin J.P., Karttunen T.J., Tuppurainen K., Davalos V., et al.  Serrated carcinomas form a subclass of colorectal cancer with distinct molecular basis. Oncogene. 2007;26:312–320. doi: 10.1038/sj.onc.1209778.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/sj.onc.1209778</ArticleId>
            <ArticleId IdType="pubmed">16819509</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>De Robertis M., Loiacono L., Fusilli C., Poeta M.L., Mazza T., Sanchez M., Marchionni L., Signori E., Vescovi A.L., Garcia-foncillas J., et al.  Dysregulation of EGFR Pathway in EphA2 Cell Subpopulation Significantly Associates with Poor Prognosis in Colorectal Cancer. Clin. Cancer Res. 2018;23:159–170. doi: 10.1158/1078-0432.CCR-16-0709.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-16-0709</ArticleId>
            <ArticleId IdType="pmc">PMC5822042</ArticleId>
            <ArticleId IdType="pubmed">27401248</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Feng J., Zhang Q., Jin Q., Liang H., Sugimura H., Zhang S., Wang J. High expression of EphA4 is associated with invasion and lymph node metastasis in colorectal carcinomas. Int. J. Clin. Exp. Pathol. 2017;10:9697–9703.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6966004</ArticleId>
            <ArticleId IdType="pubmed">31966851</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Drucker A., Arnason T., Yan S.R., Aljawad M., Thompson K., Huang W. Ephrin B2 Receptor and Microsatellite Status in Lymph Node-Positive Colon Cancer Survival 1. Transl. Oncol. 2013;6:520–527. doi: 10.1593/tlo.13385.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1593/tlo.13385</ArticleId>
            <ArticleId IdType="pmc">PMC3799194</ArticleId>
            <ArticleId IdType="pubmed">24151532</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jang B.G., Kim H.S., Chang W.Y., Bae J.M., Kang G.H. Prognostic Significance of EPHB2 Expression in Colorectal Cancer Progression. J. Pathol. Transl. Med. 2018;52:298–306. doi: 10.4132/jptm.2018.06.29.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4132/jptm.2018.06.29</ArticleId>
            <ArticleId IdType="pmc">PMC6166016</ArticleId>
            <ArticleId IdType="pubmed">30016858</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jang B.G., Kim H.S., Bae J.M., Kim W.H., Hyun C.L., Kang G.H. Expression profile and prognostic significance of EPHB3 in colorectal cancer. Biomolecules. 2020;10:602.  doi: 10.3390/biom10040602.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/biom10040602</ArticleId>
            <ArticleId IdType="pmc">PMC7226026</ArticleId>
            <ArticleId IdType="pubmed">32294981</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ulivi P., Scarpi E., Chiadini E., Marisi G., Valgiusti M., Capelli L., Casadei Gardini A., Monti M., Ruscelli S., Frassineti G.L., et al.  Right- vs. left-sided metastatic colorectal cancer: Differences in tumor biology and bevacizumab efficacy. Int. J. Mol. Sci. 2017;18:1240.  doi: 10.3390/ijms18061240.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/ijms18061240</ArticleId>
            <ArticleId IdType="pmc">PMC5486063</ArticleId>
            <ArticleId IdType="pubmed">28598398</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li S., Hou X., Wu C., Han L., Li Q., Wang J., Luo S. MiR-645 promotes invasiveness, metastasis and tumor growth in colorectal cancer by targeting EFNA5. Biomed. Pharmacother. 2020;125:109889. doi: 10.1016/j.biopha.2020.109889.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.biopha.2020.109889</ArticleId>
            <ArticleId IdType="pubmed">32036212</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jubb A.M., Zhong F., Bheddah S., Grabsch H.I., Frantz G.D., Mueller W., Kavi V., Quirke P., Polakis P., Koeppen H. EphB2 is a prognostic factor in colorectal cancer. Clin. Cancer Res. 2005;11:5181–5187. doi: 10.1158/1078-0432.CCR-05-0143.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-05-0143</ArticleId>
            <ArticleId IdType="pubmed">16033834</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lodola A., Giorgio C., Incerti M., Zanotti I., Tognolini M. European Journal of Medicinal Chemistry Targeting Eph/ephrin system in cancer therapy. Eur. J. Med. Chem. 2017;142:152–162. doi: 10.1016/j.ejmech.2017.07.029.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ejmech.2017.07.029</ArticleId>
            <ArticleId IdType="pubmed">28780190</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Barquilla A., Pasquale E.B. Eph Receptors and Ephrins: Therapeutic Opportunities. Annu. Rev. Pharmacol. Toxicol. 2015;55:465. doi: 10.1146/annurev-pharmtox-011112-140226.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1146/annurev-pharmtox-011112-140226</ArticleId>
            <ArticleId IdType="pmc">PMC4388660</ArticleId>
            <ArticleId IdType="pubmed">25292427</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dekker E., Tanis P.J., Vleugels J.L.A., Kasi P.M., Wallace M.B. Colorectal cancer. Lancet. 2019;394:1467–1480. doi: 10.1016/S0140-6736(19)32319-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0140-6736(19)32319-0</ArticleId>
            <ArticleId IdType="pubmed">31631858</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hertz D.L., Dockter T.J., Satele D.V., Loprinzi C.L., Le-Rademacher J. Neuropathy severity at the time of oxaliplatin treatment alteration in patients with colon cancer (Alliance A151912) Support. Care Cancer. 2021;29:7855–7863. doi: 10.1007/s00520-021-06371-x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00520-021-06371-x</ArticleId>
            <ArticleId IdType="pmc">PMC8551013</ArticleId>
            <ArticleId IdType="pubmed">34176021</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mao W., Luis E., Ross S., Silva J., Tan C., Crowley C., Chui C., Franz G., Senter P., Koeppen H., et al.  EphB2 as a therapeutic antibody drug target for the treatment of colorectal cancer. Cancer Res. 2004;64:781–788. doi: 10.1158/0008-5472.CAN-03-1047.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-03-1047</ArticleId>
            <ArticleId IdType="pubmed">14871799</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang A.L., Li Y., Zhao Q., Fan L.Q. Formononetin inhibits colon carcinoma cell growth and invasion by microRNA-149-mediated EphB3 downregulation and inhibition of PI3K/AKT and STAT3 signaling pathways. Mol. Med. Rep. 2018;17:7721–7729. doi: 10.3892/mmr.2018.8857.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3892/mmr.2018.8857</ArticleId>
            <ArticleId IdType="pmc">PMC5983960</ArticleId>
            <ArticleId IdType="pubmed">29620230</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>DiPrima M., Wang D., Tröster A., Maric D., Terrades-Garcia N., Ha T., Kwak H., Sanchez-Martin D., Kudlinzki D., Schwalbe H., et al.  Identification of Eph receptor signaling as a regulator of autophagy and a therapeutic target in colorectal carcinoma. Mol. Oncol. 2019;13:2441–2459. doi: 10.1002/1878-0261.12576.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/1878-0261.12576</ArticleId>
            <ArticleId IdType="pmc">PMC6822245</ArticleId>
            <ArticleId IdType="pubmed">31545551</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Arnold D., Lueza B., Douillard J.Y., Peeters M., Lenz H.J., Venook A., Heinemann V., Van Cutsem E., Pignon J.P., Tabernero J., et al.  Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials. Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. 2017;28:1713–1729. doi: 10.1093/annonc/mdx175.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/annonc/mdx175</ArticleId>
            <ArticleId IdType="pmc">PMC6246616</ArticleId>
            <ArticleId IdType="pubmed">28407110</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Heinemann V., von Weikersthal L.F., Decker T., Kiani A., Vehling-Kaiser U., Al-Batran S.-E., Heintges T., Lerchenmüller C., Kahl C., Seipelt G., et al.  FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): A randomised, open-label, phase 3 trial. Lancet Oncol. 2014;15:1065–1075. doi: 10.1016/S1470-2045(14)70330-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1470-2045(14)70330-4</ArticleId>
            <ArticleId IdType="pubmed">25088940</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Van Cutsem E., Köhne C.H., Láng I., Folprecht G., Nowacki M.P., Cascinu S., Shchepotin I., Maurel J., Cunningham D., Tejpar S., et al.  Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: Updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J. Clin. Oncol. 2011;29:2011–2019. doi: 10.1200/JCO.2010.33.5091.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2010.33.5091</ArticleId>
            <ArticleId IdType="pubmed">21502544</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cuyàs E., Queralt B., Martin-Castillo B., Bosch-Barrera J., Menendez J.A. EphA2 receptor activation with ephrin-A1 ligand restores cetuximab efficacy in NRAS-mutant colorectal cancer cells. Oncol. Rep. 2017;38:263–270. doi: 10.3892/or.2017.5682.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3892/or.2017.5682</ArticleId>
            <ArticleId IdType="pubmed">28560458</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Qu L., Chen Y., Zhang F., He L. The lncRNA DLGAP1-AS1/miR-149-5p/TGFB2 axis contributes to colorectal cancer progression and 5-FU resistance by regulating smad2 pathway. Mol. Ther. Oncolyt. 2021;20:607–624. doi: 10.1016/j.omto.2021.01.003.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.omto.2021.01.003</ArticleId>
            <ArticleId IdType="pmc">PMC7985718</ArticleId>
            <ArticleId IdType="pubmed">33816780</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ieguchi K., Tomita T., Takao T., Omori T., Mishima T., Shimizu I., Tognolini M., Lodola A., Tsunoda T., Kobayashi S., et al.  Analysis of adam12-mediated ephrin-a1 cleavage and its biological functions. Int. J. Mol. Sci. 2021;22:2480.  doi: 10.3390/ijms22052480.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/ijms22052480</ArticleId>
            <ArticleId IdType="pmc">PMC7957476</ArticleId>
            <ArticleId IdType="pubmed">33804570</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ieguchi K., Maru Y. Savior or not: ADAM17 inhibitors overcome radiotherapy-resistance in non-small cell lung cancer. J. Thorac. Dis. 2016;8:E813. doi: 10.21037/jtd.2016.07.56.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.21037/jtd.2016.07.56</ArticleId>
            <ArticleId IdType="pmc">PMC4999676</ArticleId>
            <ArticleId IdType="pubmed">27618869</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
